Abstract
Patients with pycnodysostosis, a rare skeletal dysplasia, present with bone abnormalities such as short stature, acroosteolysis of distal phalanges, and skull deformities. The disease is caused by a deficiency of the cysteine protease cathepsin K which is responsible for degradation of collagen type I and other bone proteins. Osteoclasts, bone cells of hematopoietic origin responsible for bone mineral as well as protein matrix degradation, are dysfunctional in patients with pycnodysostosis due to mutations in the cathepsin K gene. Cathepsin K deficient osteoclasts can demineralize bone but cannot degrade the protein matrix. Mutations in the cathepsin K gene disrupting wild type cathepsin K activity have been described in patients with pycnodysostosis. Animal models of cathepsin K deficiency have been created and provide a valuable tool to study osteoclast function and treatment for cathepsin K deficiency. Understanding the regulation and role of cathepsin K in osteoclast function is important for designing future therapies for pycnodysostosis. Cathepsin K inhibitors will be useful in pathological processes involving excess osteoclast activation and bone resorption such as osteoporosis, bone metastasis and multiple myeloma. This review will discuss the bone remodeling cycle, the human disease pycnodysostosis caused by cathepsin K deficiency and cathepsin K activity and regulation.
Keywords: osteopetrosis, pycnodysostosis, cathepsin k, osteoclast, osteoblast, bone remodeling
Current Molecular Medicine
Title: Pycnodysostosis: Role and Regulation of Cathepsin K in Osteoclast Function and Human Disease
Volume: 2 Issue: 5
Author(s): Gabriela Motyckova and David E. Fisher
Affiliation:
Keywords: osteopetrosis, pycnodysostosis, cathepsin k, osteoclast, osteoblast, bone remodeling
Abstract: Patients with pycnodysostosis, a rare skeletal dysplasia, present with bone abnormalities such as short stature, acroosteolysis of distal phalanges, and skull deformities. The disease is caused by a deficiency of the cysteine protease cathepsin K which is responsible for degradation of collagen type I and other bone proteins. Osteoclasts, bone cells of hematopoietic origin responsible for bone mineral as well as protein matrix degradation, are dysfunctional in patients with pycnodysostosis due to mutations in the cathepsin K gene. Cathepsin K deficient osteoclasts can demineralize bone but cannot degrade the protein matrix. Mutations in the cathepsin K gene disrupting wild type cathepsin K activity have been described in patients with pycnodysostosis. Animal models of cathepsin K deficiency have been created and provide a valuable tool to study osteoclast function and treatment for cathepsin K deficiency. Understanding the regulation and role of cathepsin K in osteoclast function is important for designing future therapies for pycnodysostosis. Cathepsin K inhibitors will be useful in pathological processes involving excess osteoclast activation and bone resorption such as osteoporosis, bone metastasis and multiple myeloma. This review will discuss the bone remodeling cycle, the human disease pycnodysostosis caused by cathepsin K deficiency and cathepsin K activity and regulation.
Export Options
About this article
Cite this article as:
Motyckova Gabriela and Fisher E. David, Pycnodysostosis: Role and Regulation of Cathepsin K in Osteoclast Function and Human Disease, Current Molecular Medicine 2002; 2 (5) . https://dx.doi.org/10.2174/1566524023362401
DOI https://dx.doi.org/10.2174/1566524023362401 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
Call for Papers in Thematic Issues
Molecular and Cellular Mechanisms in Vertigo / Vestibular Disorders
Vertigo and vestibular diseases are common among middle-aged and older adults, significantly increasing the risk of falls and leading to injuries and disabilities. Despite their prevalence, therapeutic advancements are hindered by a limited understanding of the underlying molecular and cellular mechanisms. This Special Issue is dedicated to bridging this gap ...read more
Related Journals

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Isoprenylation of Intracellular Proteins as a New Target for the Therapy of Human Neoplasms: Preclinical and Clinical Implications
Current Drug Targets Targeting Phospholipase D-mediated Survival Signals in Cancer
Current Signal Transduction Therapy CD44 - a New Cardiovascular Drug Target or Merely an Innocent Bystander?
Cardiovascular & Hematological Disorders-Drug Targets Development of WT1 Peptide Cancer Vaccine Against Hematopoietic Malignancies and Solid Cancers
Current Medicinal Chemistry The Cytoskeleton as a Therapeutic Target in Childhood Acute Leukemia:Obstacles and Opportunities
Current Drug Targets NCRNA Combined Therapy as Future Treatment Option for Cancer
Current Pharmaceutical Design Autologus Stem Cell Transplatation as a Care Option in Elderly Patients. A Review
Anti-Cancer Agents in Medicinal Chemistry The Diagnostic Value of Abnormal Bone Marrow Signal Changes on Magnetic Resonance Imaging: Is Bone Marrow Biopsy Essential?
Current Medical Imaging Heat Shock Proteins in Cancer: Signaling Pathways, Tumor Markers and Molecular Targets in Liver Malignancy
Protein & Peptide Letters Cancer Stemness as a Target for Immunotherapy is Shaped by Proinflammatory Stress
Current Stem Cell Research & Therapy miR-149 as a Potential Molecular Target for Cancer
Current Medicinal Chemistry Peptides Targeting Estrogen Receptor Alpha-Potential Applications for Breast Cancer Treatment
Current Pharmaceutical Design Dendrimer-Curcumin Conjugate: A Water Soluble and Effective Cytotoxic Agent Against Breast Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Advances in Peptide Pharmaceuticals
Current Pharmaceutical Biotechnology Mechanisms of Resistance to Photodynamic Therapy
Current Medicinal Chemistry Increased OPG Expression and Impaired OPG/TRAIL Ratio in the Aorta of Diabetic Rats
Medicinal Chemistry In Vitro Models of Human T Cell Development: Dishing Out Progenitor T Cells
Current Immunology Reviews (Discontinued) Targeting the Ataxia Telangiectasia Mutated Protein in Cancer Therapy
Current Drug Targets 18F-Fluorodeoxyglucose PET/CT and MRI Imaging Characteristics of Monomorphic Epitheliotropic Intestinal T-cell Lymphoma: A Case Report
Current Medical Imaging Nuclear Export Mediated Regulation of MicroRNAs: Potential Target for Drug Intervention
Current Drug Targets